Evaluation of a new premedication protocol for administration of equine rabies immunoglobulin in patients with hypersensitivity.

This research evaluates a new protocol developed for safer administration of equine rabies immunoglobulin (ERIG) in patients who show hypersensitive reactions, demonstrating that the protocol is safe and doesn’t obstruct immune response to the vaccine and ERIG therapy.

Objective of the Research

• The main goal of the research was to standardize skin testing and create a safe and effective protocol for administrating ERIG in patients who show positive skin test and hypersensitivity reactions.

Methods Used in the Research

• A grading system for skin testing was developed using injection histamine as a positive standard to validate the procedure.
• This procedure was tested on 517 subjects who were severely exposed to rabies according to the World Health Organization’s (WHO) category III classification.
• A premedication protocol was developed, which involves administering injections of pheniramine, ranitidine, hydrocortisone, and adrenaline.
• This protocol was then tested on 51 subjects who showed positive skin test reactions or hypersensitivity to ERIG.

Results of the Research

• The results showed that the premedication protocol was safe and efficient, as none of the 51 subjects participating in the protocol showed adverse reactions to ERIG, despite previously established hypersensitivity.
• The premedication protocol did not negatively impact the immune response to the rabies vaccine and ERIG therapy, implying that the effectiveness of the therapy is not compromised.

Key Takeaways

• The research study successfully developed and tested a safe and effective premedication protocol for the administration of ERIG in patients undergoing rabies treatment who show hypersensitivity reactions.
• This protocol helps in requiring full ERIG doses even to those who were previously hypersensitive, without impacting the body’s immune response.
• The results from this study are promising and could potentially lead to better management of ERIG administration in hypersensitive patients in the future.